Get a glimpse into our company and investor data—powered by the PitchBook Platform
Molecular testing PROGENSA PCA3 assay diagnostic application. The asset develops diagnostic application for the detection of prostate cancer.
This information is reserved for PitchBook Platform users. To explore DiagnoCure (PCA3 Prostate Cancer Biomarker Assets)‘s full profile, request access.
© 2019 PitchBook Data. All rights reserved. PitchBook is a financial technology company that provides data on the capital markets.